Do the ASCO/CAP 2007 HER2 testing guidelines improve prediction of benefit to adjuvant trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant trial.
- Citation:
- Cancer Res vol 69 (24 Suppl 3) abstr 701
- Meeting Instance:
- SABCS 2009
- Year:
- 2009
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 161
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- E. A. Perez M. M. Reinholz A. C. Dueck K. S. Tenner N. E. Davidson J. R. Gralow L. N. Harris L. A. Kutteh R. B. Jenkins B. Chen
- Networks:
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: